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Abstract
THE EFFECT OF A 20-25 CALORIES % FAT DIET ON 




Fourteen males with elevated blood lipids were given a 20-2.5 Calories % 
fat diet for 2S days. Fasting blood samples were drav/n at zero, two, and four 
weeks and analyzed for plasma TXB2 and serum lipids. Plasma TX32 was 
significantly increased the first two weeks with a subsequent decrease the final 
two weeks. Values were still significantly elevated at four weeks when 
compared with initial values. Serum cholesterol, HDL cholesterol, and LDL 
cholesterol were significantly decreased over the four-week period, 
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Thromboxane A2 is a prostaglandin identified in human platelets by 
Svensson, Hamberg, and Samuelsson in 1975 (1, 2). Thromboxane A2 was first 
known as a rabbit aorta contracting substance (RCS), a name coined by Piper 
and Vane (3) because of its ability to contract isolated rabbit aorta. This RCS 
was found to have two active components, one being more potent than the 
other. The less active component had a half life of about five minutes and was 
identified as being the prostaglandin endoperoxides PGG2 and PGH2. The more 
potent substance was an unstable compound with a half life of about 30 seconds. 
This substance was named thromboxane A2 and was detected as an unstable 
intermediate in the conversion of PGG2 to TXB2. Thromboxane B2 is the stable 
inactive metabolite of TXA2 (1, 2).
Prostaglandins are synthesized from 20-carbon polyunsaturated fatty 
acids which are constituents of phospholipids found in the cell membrane of all 
mammalian tissues. Their structure is characterized by a cyclopentane ring 
with two aliphatic side chains. Thromboxanes have similar side chains but 
differ from the primary prostaglandins in having an oxane ring structure (see 
Figure 1) (4). Arachidonic acid is the main precursor in man and gives rise to 
thromboxane A2 along with the other 2-series prostaglandins (PGE2, PGF2 
PGD2 and prostacyclin or PGI2) (5). Dihomo-y-linolenic acid which is a trienoic 
analog of arachidonic acid, gives rise to the 1-series and is present at much 
smaller concentrations. Eicosapentaenoic acid, precursor of the 3-series, is 
normally absent in the body (6, 7). Thromboxane A2 aggregates platelets and is 
a powerful vasoconstrictor (2). It has been shown to be produced in platelets, 









Figure 1. Basic Structure of the (1) Prostaglandins Which are Differentiated 






The synthesis of thromboxane A2 from arachidonic acid is shown in Figure 
2 (9). Arachidonic acid is esterified and fixed mainly in membrane phospholipid. 
It must be liberated from the phospholipid before it can be metabolized by 
oxidative tissue enzymes. This liberation is thought to be accomplished by 
phospholipase A2. In platelets, phospholipase A2 requires calcium for its 
biochemical activity which could act as a regulating mechanism (10). The 
activation of phospholipase A2 occurs through a chemical or physical stimula­
tion of the cell membrane (11). Arachidonic acid is then released from the
second position of phospholipid molecules, principally phosphatidyl choline and 
phosphatidyl inositol (9). Several proposed inhibitors of phospholipase A2 are 
glucocorticosteroids, steroid anti-inflammatory drugs, and Mepacrine (10).
There are several pathways for the metabolism of arachidonic acid once it 
is released from the phospholipid molecule in platelets and lung homogenates
(10).
It may be the substrate for the animal lipoxygenase synthesis of 12-
hydroperoxyarachidonic acid (HPETE) and its hydroxyacid (HETE). The phy­
siological significance of this is unknown, but HPETE has been claimed to
inhibit TXA2 synthetase.
There may also be a spontaneous auto-oxidation to 15-hydro-peroxyara-
chidonic acid (15-HPAA).
Of primary importance to this paper is the cyclization of arachidonic acid 
and inclusion of molecular oxygen to form the unstable intermediate prosta­
glandin endoperoxides PGG2 and PGH2. The enzyme responsible for this action 
is cyclo-oxygenase which is present in the plasma membrane or endoplasmic 
reticulum (12).
PGH2 is further metabolized in platelets by thromboxane synthetase to
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TXA2 which is spontaneously hydrolyzed to TXB2» In vascular tissue it is 
converted by prostacyclin synthetase to prostacylin (PGI2) and its metabolite 6- 
keto-PGFjQ; (Figure 2). PGH2 is also converted to the stable primary prosta­
glandins PGE2, PGF2a > anci PGD2. This occurs either nonenzymatically or 
through isomerase or reductase enzymes (12).
12L-hydroxy-5, 8, 10-heptadecatrienoic acid (HHT) and Malondialdehyde 
(MDA) are also metabolites of the prostaglandin endoperoxides (10).
There are several known inhibitors of cyclo-oxygenase. They are: (1) 
aspirin, which has an irreversible action and persists as long as platelet life, (2) 
indomethacin, (3) phenylbutazone, (4) fenoprofen, and (5) sulfinpyrazone. The 
effects of these last four are lost when they or their metabolites are removed 
from the circulation (9).
Role of Thromboxane A? in Platelet Aggregation
Thromboxane A2 as referred to earlier is a proaggregatory, vasocon- 
stricting substance synthesized in platelets (13, 14). Prostacyclin formed in the 
blood vessel wall has opposite effects. It is a powerful anti-aggregating and 
vasodilating substance (10). The opposing effects of these two products of 
arachidonic acid metabolism is shown in Figure 3 (15).
Their physiological effects are mediated through the regulation of c-AMP 
levels. It is proposed that prostacyclin stimulates platelet adenylate cyclase, 
inhibits calcium mobilization, and thus prevents platelet aggregation. Throm­
boxane A2 lowers c-AMP levels in platelets, stimulates calcium mobilization 
and, therefore, leads to platelet aggregation (10). A balance between TXA2 and 
prostacyclin provides a homeostatic mechanism between platelets and the 










The Opposing Effects of Prostacyclin and Thromboxane ^ (15).Figure 3.
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An interaction between platelets and the vessel wall seems to occur. 
When platelets become in close contact with the vessel wall, they release their 
own prostaglandin endoperoxides which can then be used by the endothelial cells 
to synthesize prostacyclin. Platelets are then dispersed under the action of 
prostacyclin and further aggregation leading to thrombus formation will be 
prevented (5).
When the endothelial wall is damaged, platelets tend to clump and adhere 
to the vessel wall. Platelets undergo shape change and secrete the contents of 
their granules including TXA2, promoting platelet aggregation and thrombus 
Platelet contact with a healthy wall does not stimulate thisformation.
clumping (11).
It is clearly seen that an upset in the balance between TXA2 and 
prostacyclin would lead to increased platelet aggregation, thrombus formation, 
and possibly atherosclerosis. Other factors related to atherosclerosis such as 
high cholesterol, cigarette smoking, and diabetes have also been related to 
increased platelet aggregability (16-18). Nicotine seems to have a selective 
inhibitory effect on prostacyclin which may explain the increased stickiness of 
platelets reported in smokers (19).
Dietary Factors
A high polyunsaturated fatty acid diet has been shown to significantly 
reduce platelet aggregation (20) and produce changes in platelet function tests 
suggesting decreased platelet activation (21). Linoleic acid is also found to 
decrease arterial thrombus formation (22). Thus, a relationship between the 
synthesis of prostaglandins and diet is thought to occur.
Synthesis of prostaglandins may be depressed by linoleic acid. A high
11
intake of this fatty acid in animals results in its accumulation in platelet 
phospholipids, replacing arachidonic acid which is a precursor for prostaglandins 
(6). In this way, prostaglandin synthesis is inhibited. Conversion of linoleate to 
arachidonate may be enhanced in certain tissues when dietary linoleate is low
(7).
Eicosapentaenoic acid (EPA) has been regarded as a possible therapeutic 
agent in prevention of atherosclerosis. Eskimos in Greenland have been shown
to have a high content of EPA in the blood which probably originates from the 
high content of EPA in the diet. These Eskimos have a delayed atherosclerotic 
process and an increased tendency to bleed (23). Dyerberg, et al. suggests that 
EPA forms PGI3 and TXA3, prostaglandins of the 3-series. Since EPA has not 
been found to be a pro-aggregating agent, it is proposed that TXA3 is inactive 
while PGI3 is a potent anti-aggregating agent. This would shift the balance 
toward an anti-aggregating state (23). 
prostaglandins of the 3-series were hardly formed in a cod-liver oil diet (high- 
EPA) given to rats. He suggests the low thrombogenicity is due to depressed 
TXA2 and PGI2 production and possibly more of a decrease in platelet TXA2 
production pushing the balance toward an anti-thrombogenic state (24).
In a recent study, a diet rich in EPA was found to increase bleeding time
Acetylsalicylic acid (ASA) given with the diet 
prolonged bleeding time longer than did ASA and the diet separately. The 
authors conclude that EPA in the diet affects the interaction between platelets 
and vessel walls other than altering prostaglandin synthesis (25).
Linolenic acid which can be converted to EPA in some species (22) may 
also be important. According to Lanzola, the ratio of linoleic to linolenic acid 
is related to their physiological effects (26).
However, Hornstra observed that
and depress aggregation.
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High levels of linoleic acid in the diet may decrease TXB2 production in 
platelets. Galli and his associates have shown a decreased production of TXB2 
in platelets of rabbits fed corn oil as compared to that produced in platelets of 
butter-fed animals. Subsequent reduction of the sensitivity of linoleic acid rich 
platelets to the aggregating action of arachidonic acid was observed (27). A 
diet high in polyunsaturated fatty acids may be beneficial to persons with 
atherosclerotic heart disease because of its anti-aggregating and TXB2 lowering 
ability. The purpose of the present study is to measure changes in TXB2 
production in human subjects on a low fat, high polyunsaturated fatty acid diet.
METHODOLOGY
Subjects
Fourteen men between the ages of 32 and 76 volunteered to participate in 
this research project. Names were obtained from the cardiac rehabilitation 
program at Loma Linda Universty and through advertising in the local area. 
Criteria for selection were serum cholesterol above 220 and/or serum trigly­
cerides above 133 or if they had experienced a heart attack. The subjects were 
fed three meals a day for twenty-eight days. Breakfast and supper were served 
in the Department of Nutrition research kitchen and a sack lunch was provided 
for the noon meal.
Diet
A ten-day cycle lacto-ovo-vegetarian menu was designed for this project 
(see Appendix). The meals met the RDA for all nutrients and had 20-25%
calories supplied by fat, 14-17% calories supplied by protein, and approximately 
60-65% calories supplied by carbohydrate. The mean P/S ratio of the diet was 
3.6, and the mean calorie level was 1,952. 
grams or less per day (see Appendix for complete breakdown of each day's 
nutrients relevant to this study).
Sodium content was kept at five
The menu was designed to include foods 
typical of the American diet but with appropriate substitutions to lower fat and
cholesterol content. For example, skim milk, egg substitute, low fat, low 
cholesterol cheese, and fat free salad dressing was used, 
fat was liquid safflower oil which was added to food in cooking since no visible
The main source of
fats were allowed.
Subjects ate only the food given them. They were instructed not to smoke 
or consume alcohol during the study period. Herb tea and cereal beverages 
were unlimited. Subjects were also instructed not to take aspirin during the
13
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study period since it has been shown to inhibit prostaglandin synthesis (28).
Thromboxane Determination
A fasting blood sample was drawn into tubes containing EDTA. Blood was 
drawn the first day, at two weeks, and at the end of the study period. 
Breakfast was served immediately after blood drawing.
The blood sample was centrifuged and the plasma separated and frozen. 
The plasma samples were analyzed for thromboxane B2 by radioimmunoassay as 
described by Granstrom (29).
The following reagents were used:
Assay Buffer. This buffer consists of 50 ju M phosphate, 0.1% gelatin 
and 0.01% thimerosal, adjusted to pH 7.3.




3. Phosphate Buffer. Consists of 6.8 g KH2PO4, 1.0 g gelatin, 0.1 g
thimerosal, diluted to one liter with distilled water and adjusted to pH 7.3.
4. Thromboxane B? Standard. Purchased from the Upjohn Company, 
Kalamazoo, Michigan and diluted to 100 ng/ml.
Radiolabeled Thromboxane B?. ^H-TXB2 tracer was purchased from 
New England Nuclear, Boston, Massachusetts. The 0.025 mCi/.25 ml Ethanol 
(125.0 Ci/m M) was added to 2.5 ml Ethanol and 100 ju 1 of that was diluted to
5.
10 ml with phosphate buffer.
Antiserum to Thromboxane 69. Rabbit antiserum to TXB2 was6.
purchased from Seragen, Inc., Boston, Massachusetts.
A 25% w/v (250 g/liter PEG) was7. Polyethylene Glycol (PEG).
prepared in distilled water and used to separate the antibody bound and free
fractions.
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8. Scintillation Fluid. The scintillation fluid used was Fred Snyder's
modified Bray's solution (30).
All tests were run in duplicate in 12 x 75 mm polypropylene test tubes 
according to the protocol in Table 1. The samples were run in 50 m! and 100 Ml 
dilutions. Six standard dilutions (5, 10, 25, 50, 100, and 250 pg/ml) were 
prepared and run before and after each set of samples. A plasma sample with a 
known amount of TXB2 was used as a quality control (QC-1).
After addition of the antisera, the tubes were incubated for 16 hours at 
4°C. At the end of the incubation, tubes were placed in an ice bath. Plasma 
buffer and PEG were added to each tube and vortex mixed vigorously for 5-10 
seconds. The tubes were centrifuged immediately at 4°C for 30 minutes at 
3400 rpm (1500 x g). After centrifugation, the supernatants were decanted and 
the precipitants redissolved in 1 ml of distilled water. The tubes were placed in 
a warm water bath and vortex mixed intermittently until the precipitate was 
completely dissolved. The resuspended precipitate was then transferred to 
polypropylene scintillation vials and counted with 10 mlmodified Bray's for 10
minutes.
Concentration of TXB2 in the samples is determined from the standard
curve. Calculations are as follows:
1. Counts per minute (cpm) for each set of duplicates are averaged.
2. Net counts for all samples are determined by subtracting from each 
the average plasma blank counts. Net counts for all standards are determined 
by subtracting from each the average buffer blank counts.
3. To determine the percent bound (96 B) for each standard and sample, 
divide the average net cpm by the average net cpm of the total counts tubes.
16
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4. Calculate the normalized percent bound (% B/B0) for each standard 
and sample as follows:
% b/Bq = % B of Standard or Sample x 100% 
% B of "o" Standard
5. Using semi-logarithmic graph paper, plot % B/B0 for each standard 
versus the corresponding picograms (pg) TXB2 added.
6. Determine the pg TXB2 in each sample by interpolation from the
standard curve.
Total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides
were determined by the Faculty Medical Staff Lab.
RESULTS AND DISCUSSION
Fourteen male subjects were given a 20-25 Calories % fat, high 
polyunsaturated fatty acid diet for 28 days. All subjects completed the study 
except for subject //13 who dropped out after the second week due to illness. 
Plasma samples were collected and thromboxane B2 levels were measured by 
radioimmunoassay. Paired t-tests were used to analyze the data.
A 20-25 Calories % fat, high polyunsaturated fatty acid diet significantly 
increased plasma TXB2 levels (Tables 2 and 3). A rise in TXB2 was observed 
between initial values and those at two weeks with a decrease between weeks
two and four. However, TXB2 was still significantly elevated at the fourth 
week when compared with the initial values.
These results differ with previous data presented by Galli, et al. indicat­
ing that TXB2 synthesis is depressed on a high linoleic acid diet (27). Linoleic 
acid is also known to replace arachidonic acid in platelet phospholipids implying 
an inhibition of prostaglandin and thromboxane synthesis (6).
It is difficult to explain our results in light of the current research done 
thus far. The inconsistent pattern observed may be due in part to the 
instability of TXB2 under storage conditions. McCann, et al. report that 
prolonged storage of TXB2 for one month or more at -20°C was unsatisfactory. 
Initial values of TXB2 compared with those at one, two, three and four months 
of storage showed predominantly losses of TXB2, but occasionally there were 
marked increases (31). Initially, we were unaware of this storage problem and 
our plasma samples were frozen for three months before analysis was done.
Plasma levels of 6-keto-PGFj # (stable metabolite of prostacyclin) were 
also measured and reported by Violet Komm, Loma Linda University Masters 




Table 2. Mean Change and Standard Error of Plasma 
TXB2, 6-keto-PGF Iq, and Serum Lipid Levels.
4-8 Weeksb2^4 Weeks a 0-4 Weeks0-2 Weeks




















-9 ± 3 
(p < .05)
7 ± 3 
(p < .025)
1 ± 2 
(N.S.)








29 ± 19 
(N.S.)




22 ± 14 
(N.S.)
38 ± 65 
(N.S.)
-106 ± 96 
(N.S.)




-7 ± 35 
(N.S.)
101 ± 58 
(N.S.)
53 ± 37 
(N.S.)
1«
aWhen comparing values at 4 weeks means used included only the 13 subjects who 
completed the study.
T_
DOnly serum lipids were measured at 8 weeks. 
cNull hypothesis: Change is not significantly different from zero. 
dData used is from Violet Komm, Loma Linda University Masters Thesis March 1982.
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Table 3. Mean Plasma TXB2 Levels in 14 Human Subjects.8
0-2 Weeks — p<.01^ 
p < .05 
p < .025




rs 140 - 
120 - 
100 -







J (47 ± 5C)cd0Js 40 - 
20 -
J (32 ± 6C)
+ +
0 2 4
Weeks on 20-25 Calories % Fat Diet
aMeans do not include data from subject No. 13.
DNull hypothesis: Change is not significantly different from zero.
cStandard error.
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Changes in serum lipids were also measured (Table 2). Serum cholesterol 
levels were significantly decreased by the low 20-25 Calories % fat, high 
polyunsaturated fatty acid diet. Most of the decrease in serum cholesterol took 
place during the first two weeks with a small insignificant decrease occurring 
during the final two weeks. The cholesterol lowering effect of this diet may be 
beneficial in preventing coronary heart disease. Miettinen, et al. found that a 
cholesterol-lowering diet was associated with a significant decrease in 
mortality from coronary heart disease in men (32).
Measurement of serum cholesterol four weeks after the end of the study
period showed a significant increase back toward the baseline values. Both 
HDL and LDL cholesterol were significantly reduced over the four-week period. 
Measurement of these variables four weeks after the end of the study period 
showed a tendency to increase, but this increase was not significant. No 
significant changes were observed in serum triglyceride levels.
Blood lipid levels appear to be related to the metabolism of prosta­
glandins. High serum cholesterol levels have been related to an increased 
production of TXB2 in isolated platelets (33, 34). High levels of triglycerides 
may be related to a decrease in prostacyclin levels in the serum (35). Several 
significant correlations which were observed between TXB2, 6-keto-PGFiQ., and 
serum lipids are reported in Table 4.
22















txb2 N.S. -.5085 
(P < -05)
N.S.
aPearson correlation coefficient is used.
^Null hypothesis: Correlation is not significantly different from zero.
SUMMARY
Fourteen male subjects with elevated lipid levels were given a low (20-25 
Calories %) fat, high polyunsaturated fatty acid diet for 28 days. Fasting blood 
samples were drawn at zero, two, and four weeks and analyzed for plasma TXB2 
and serum lipids. Plasma TXB2 was significantly increased the first two weeks 
with a subsequent decrease the final two weeks. Values were still significantly 
elevated at four weeks when compared with initial values. Serum cholesterol, 
HDL cholesterol, and LDL cholesterol were significantly decreased over the 
four-week period. No significant changes were observed in serum triglycerides.
23
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Age and Weights of 14 Human Subjects on a 20 - 25 Calories % 
Fat Diet for 28 Days.
Table 5.















aa 184+ 2753+ 12Mean
a Standard deviation.
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Table 6. Plasma TXB„ Levels (pg/ml) in 14 Human Subjects.2















bbb 47+ 19142+ 12543+ 46Mean
a Subject # 13 dropped out of study after second week due to illness.
b Standard deviation.
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Serum Cholesterol Levels (mg/dl) in 14 Human Subjects.Table 7.















bb bb 235+ 50190+ 36200+ 35246+ 41Mean
a Subject # 13 dropped out of study after second week due to illness.
b Standard deviation.
31
HDL Cholesterol Levels (mg/dl) in 14 Human Subjects.Table 8.















bbbb 44+ 1437+ 1235+ 1144+ 16Mean
a Subject # 13 dropped out of study after second week due to illness.
b Standard deviation.
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LDL Cholesterol Levels (mg/dl) in 14 Human Subjects.Table 9.















143+ 49°114+ 29°132+ 35°160+ 34°Mean
ta 0 weeks because of highLDL Cholesterol could not be computed a 
triglyceride value.




Serum Triglyceride Levels (mg/dl) in 14 Human Subjects.Table 10.















bbbb 232+ 183194+ 107171+ 82291+ 361Mean
a Subject # 13 dropped out of study after second week due to illness.
b Standard deviation.
34
c(pg/ml) in 14 Human Subjects.Table 11. Plasma 6-Keto-PGF la















bbb 259+ 65207+ 89 308+ 198Mean
a Subject # 13 dropped out of study after second week due to illness.
b Standard deviation.
C Data used is from Violet Komm, Loma Linda University Masters Thesis 
M arch 1982.
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Table 12. Ten-day Lacto-ovo-vegetarian Menu
DAY 1
Breakfast
8 oz. skim milk 
1 blueberry muffin 
3/4 c. dry cereal




2 slices whole wheat bread, 2 tbsp. turkey spread, 
lettuce leaf
1 c. coleslaw + 1 tbsp. oil*
1 nectarine 
6 oz. can V-8 juice
Dinner
1 c. spaghetti with 3/4 c. sauce with 1 tsp. oil
3 tbsp. Parmesan cheese
1/2 c. spinach with lemon wedge
Lettuce salad with radishes
Zero calorie dressing
1 slice hot garlic bread
1 peachy shake
1 c. diced watermelon




1 c. skim milk 
1/2 English muffin 
1 tbsp. jelly
10 cottage fries + 1 tsp. oil 
3M c. dry cereal




1 hot dog bun, 1 Loma Linda linkett
with mustard and relish
2 carrot sticks, 2 celery sticks,
3 broccoli flowers, 3 cauliflowers 
Dressing + 2 tbsp. oil
1 orange
1 small can apple juice
Dinner
2 c. sukiaki 
1 c. rice
1 fortune cookie with tea 
Boysenberry milk shake 




1 c. skim milk 
Fruit toast
2 slices toast 
3/4 c. dry cereal 
8 oz. orange juice
Lunch
Sandwich:
2 slices bread, 1 1/8" slice bologna + 1 tsp. oil 
2 slices tomato, 1 leaf lettuce 
Garden vegetable soup 
8 oz. lemonade 
1 small banana
Dinner
1 stuffed bell pepper 
1/2 c. frozen baby carrots 
Lettuce wedge with Zero dressing 
1 slice bread 
1 tbsp. jelly
1 1/3 c. fruit juice medley 




1 c. skim milk
1 c. oatmeal + 1 tsp. oil
2 tbsp. raisins 
1 slice toast
1 tbsp. jelly
2 fresh pear halves
8 oz. orange juice or grapefruit juice
Lunch
1 vegeburger
1 hamburger bun with yogurt, sliced tomato, 
mustard, lettuce, pickles 
1 c. carrot and raisin salad 
1 small can grapefruit juice
Dinner
Vegetarian pot pie 
1 c. Italian mixed vegetables 
1/2 c. parsley potatoes 
4 small radish roses 
1/2 slice bread 
1 tbsp. jelly





1 c. skim milk 
3 4" pancakes + 1 tsp. oil 
1 c. hot cinnamon applesauce 
S oz. orange juice or 6 oz. pineapple juice
Lunch
1 c. French onion soup 
1 slice French bread 
1/2 c. potato salad
3 slices tomatoes 
1 small fresh pear
4 oz. bottle grape juice
Dinner
Tostadas—get 2 cups vegetables (lettuce, 
tomato, etc.)
2 tbsp. low-fat yogurt 
1 tbsp. hot sauce 
1/2 c. Mexican rice 
1/2 c. Mexican wax beans 





8 oz. skim milk
1/2 English muffin
1 tbsp. jelly
3/4 c. dry cereal
10 cottage fries + 2 tsp. oil









1/2 c. zuchinni italiano
1 slice Italian bread with garlic
1 c. skim milk
Lettuce salad with radishes and low calorie 
dressing





1 c. skim milk
1 c. oatmeal + 2 tsp. oil
2 tbsp. raisins
1 slice whole wheat toast 
1 tbsp. jelly




2 slices bread, 2 T. egg salad
3 carrot sticks, 3 celery sticks 3" long 




1/2 c. Mexican rice






1 c. skim milk 
1 blueberry muffin 
3/4 c. dry cereal
8 oz. orange juice or 2/3 c. apple juice 
1/2 large banana
Lunch
Fresh vegetable soup 
2 soda crackers 
1 slice low-fat cheese (1 oz.) 
1 pear
1 small can pineapple juice
Dinner
1 1/3 c. low-calorie oriental + 1 tbsp. soy sauce 
3/4 c. rice + 1 tsp. oil
1 c. oriental vegetables
2 fortune cookies + tea 
1 c. skim milk





1 c. skim milk 
Fruit toast
2 slices toast 
3/4 c. dry cereal 
8 oz. orange juice
Lunch
Sandwich:
2 slices bread, 2 tbsp. cheese spread
3 slices tomatoes, lettuce leaf
3 broccoli flowers, 3 cauliflowers 
Zero dressing
4 oz. bottle grape juice 
Dried fruit medley:
2 dried apricot halves, 1 dried pear half, 
1 dried apple ring
Dinner
Split pea and cottage cheese loaf
3/4 c. steamed broccoli
3/4 c. stewed tomatoes + 1/2 tsp. oil
1/2 baked potato with 1/4 c. grated cheese
Mock sour cream
1 slice whole wheat bread
1 tbsp. jelly
1/2 cantaloupe with 8 strawberries 




1 c. skim milk 
3 4" pancakes + 1 tsp. oil 
1 c. hot cinnamon applesauce 
1 c. orange juice or 6 oz. pineapple juice
Lunch
Sandwich:
2 slices bread, 2 tbsp. sandwich spread 
2 tomato slices, lettuce leaf 
1 large apple
Nut and raisin cup (12 peanuts, 2 T. raisins) 
1 small can tomato juice
Dinner
1 1/2 falafels with 1/2 c. garbanzos on each one
1 1/2 c. raw vegetables and 1/8 c. plain yogurt
1/2 c. tarragon carrots
Tropical shake
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